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Abstract: The combretastatins have attracted significant interest as 
small molecule therapies for cancer due to their ability to function as 
vascular disrupting agents. We have successfully prepared a range 
of combretastatin analogs that are based on a novel sydnone 
heterocycle core, and their potential as tubulin binders has been 
assessed in vitro and in vivo. The most potent candidate was found 
to disrupt microtubules and affect cellular morphology at sub-
micromolar levels. Moreover, it was found to bind reversibly to 
tubulin and significantly increase endothelial cell monolayer 
permeability, in a similar manner to combretastatin A4. Surprisingly, 
the compound did not exhibit efficacy in vivo, possibly due to rapid 
metabolism. 
Introduction 
A growing area of research has focussed on targeting the blood 
supply of tumors.[1,2] A tumor relies on a functional blood vessel 
network to grow and survive,[3] hence tumor blood vessels are 
attractive targets for anticancer drugs.[4] Of the current vascular 
targeting methods, vascular disrupting agents (VDAs) possess 
particularly desirable characteristics. By definition, VDAs cause 
the rapid and selective collapse of tumor blood vessels, resulting 
in extensive necrotic cell death within the tumor.[1] Most VDAs 
fall into two categories; analogs of flavone acetic acid (FAA)[5,6] 
and microtubule depolymerizing agents.[4]  Of these, microtubule 
depolymerizing agents have received the most attention. Indeed, 
the classical tubulin binding agent ± colchicine (Figure 1) ± has 
been known to damage tumor blood vessels since the 1930s.[7] 
However, colchicine is too toxic to use in this regard.[8] 
Structurally related to colchicine, the combretastatins were 
isolated from the Cape Bush Willow tree Combretum caffrum 
and exhibited great promise as VDAs.[9-11] The most active 
compound isolated ± combretastatin A-4 (CA4) ± instigated 
tumor blood vessel disruption within minutes at well below the 
maximum tolerated dose (MTD).[12] To aid water solubility, it was 
developed into the prodrug, disodium combretastatin A-4 3-O-
phosphate (CA4P).[13] The higher toxicity of colchicine relative to 
&$ LV WKRXJKW WR DULVH IURP GLIIHUHQFHV LQ ELQGLQJ WR WKH ȕ-
tubulin subunit. Colchicine is thought to bind pseudo-irreversibly 
leading to further downstream toxic effects, whereas CA4 binds 
reversibly.[14] The low toxicity and exciting activity of CA4P 
resulted in its evaluation as an anticancer agent in clinical trials 
as single agent and more recently in combination with 
cytarabine.[15,16]  
 
Figure 1. Structures of colchicine and CA4P. 
Despite continued interest in CA4P as a clinical candidate, there 
are a number of underlying issues with the compound. In 
particular, the cis geometry of the alkene linker is fundamental to 
its activity, with the trans isomer exhibiting essentially zero 
activity.[17] This issue is further compounded by the propensity of 
stilbenes to undergo cis-trans isomerization in heat, light and 
protic media.[18] A potential solution is the replacement of the 
alkene linker with a heterocycle.[19-24] Such a strategy essentially 
³IL[HV´ WKH OLQNHUJHRPHWU\DQGSUHYHQWV ORVVRIDFWLYLW\ WKURXJK
metabolic isomerization. Although a number of significant 
contributions have been made in the field of rigid combretastatin 
analogs, sydnone analogs have yet to be studied. Sydnones are 
unusual but stable dipolar compounds, and are referred to as 
mesoionic (Figure 2).[25] We have had a significant interest in the 
chemistry of sydnones for a number of years,[26-29] but until now 
have not studied their potential as pharmacological agents. In 
light of our development of a robust and versatile route to 
synthesize diarylsydnones,[30] we sought here to prepare a 
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number of novel sydnone-bridged combretastatin analogs and 
assess their efficacy as VDAs. 
 
Figure 2. Sydnone-based rigid analogs of CA4. 
Results and Discussion 
Chemistry 
A range of diarylsydnones were readily prepared using direct 
arylation methodology developed in our laboratories (Table 1).[30] 
Previous studies have indicated that the 3,4,5-trimethoxyphenyl 
ring is key to the activity of combretastatin analogs.[31,32] 
Therefore, we focussed the majority of our efforts into the 
synthesis of analogs containing this motif on both the N3 (entries 
1-10) and C4 (entries 11-13) of the sydnone. We were also able 
to prepare an analogue of AVE 8062, a former Sanofi Aventis 
clinical candidate, in excellent yield (Entry 9).[4] Direct analogs of 
CA4 were also readily prepared, without the use of protecting 
groups (Entries 10 and 11). 
 
Biological Evaluation 
Although a significant number of combretastatin analogs have 
been developed over the years, a general in vitro method for 
assessing their efficacy has proved elusive. A large number of 
reports focus on the direct activity of the compounds against 
cancer cells.[33] Studies from our laboratories have previously 
shown that although in vitro CA4P targets tumor cells and 
inhibits their proliferation, in vivo it is predominantly its vascular 
effects that are responsible for killing tumor cells by necrosis. [34] 
Therefore, assays involving direct action on cancer cells may not 
necessarily predict the vascular disruptive capabilities of a 
compound. Instead, VDA effects on the microtubule 
cytoskeleton of endothelial cells (the primary target of VDAs) 
and subsequent changes in cell morphology are thought to be 
integral to their therapeutic efficacy.[35] Indeed, recently, we have 
shown that assays using endothelial cells provided a good 
insight into the activity CA4 analogs that translated into in vivo 
efficacy.[36] 
 
Initial Screens 
Initially, compounds were studied for anti-proliferative activity 
against endothelial cells. 
Several N-(3,4,5-trimethoxyphenyl) (TMP) compounds had 
either low activity or were completely inactive in the assay 
(Table 2, entries 1-8). Nanomolar activity was achieved with 
more conventional analogs of CA4 (entries 9, 10 and 11). It was 
interesting to note that aniline 9 was more active than direct CA4 
analogue 10. More interesting still was that structural isomer 11 
was an order of magnitude higher in activity than 10 (entry 11). 
Indeed, compounds bearing the TMP unit at the sydnone C4 
exhibited higher activity than their N3-substituted isomers ± 12  
 
Table 1. Synthesis of sydnone-based analogs of CA4.  
 
Entry Compound Ar1 Ar2 Yield 
1 1 3,4,5-MeOC6H2 
4-MeOC6H4 73% 
2 2 3,4,5-MeOC6H2 
2-MeOC6H4 71% 
3 3 3,4,5-MeOC6H2 
Ph 81% 
4 4 3,4,5-MeOC6H2 
4-MeC6H4 96% 
5 5 3,4,5-MeOC6H2 
3-NO2C6H4 90% 
6 6 3,4,5-MeOC6H2 
2-Thiophenyl 81% 
7 7 3,4,5-MeOC6H2 
4-EtOC6H4 92% 
8 8 3,4,5-MeOC6H2 
2-ClC6H4 73% 
9 9 3,4,5-MeOC6H2 
3-H2N-4-MeOC6H3 91% 
10 10 3,4,5-MeOC6H2 
3-HO-4-MeOC6H3 81% 
11 11 3-HO-4-MeOC6H3 
3,4,5-MeOC6H2 47% 
12 12 4-EtOC6H4 
3,4,5-MeOC6H2 76% 
13 13 4-MeOC6H4 
3,4,5-MeOC6H2 71% 
14 14 4-MeOC6H4 
4-MeOC6H4 79% 
15 15 4-MeOC6H4 
Ph 83% 
16 16 4-MeOC6H4 
2-Thiophenyl 89% 
17 17 4-MeOC6H4 
2-ClC6H4 94% 
18 18 4-MeOC6H4 
3-NO2C6H4 85% 
19 19 4-EtOC6H4 
4-MeC6H4 77% 
20 20 Ph 
4-MeC6H4 83% 
 
vs 7 (entry 12 vs 7) and 13 vs 1 (entry 13 vs 1). All further 
diarylsydnones showed little to no activity (entries 14-20). As 
controls, both CA4P and colchicine were used in the assay and 
were found to be potent at low nanomolar concentrations, as 
expected. Importantly, derivatisation of 11 to the highly water-
soluble disodium phosphate salt 23 maintained activity, 
indicating that the phosphate was rapidly cleaved in media 
containing serum. The most active compounds from the initial 
screens are depicted in Figure 3. 
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Table 2. Values for growth inhibition of HUVECs by sydnone anologs versus 
CA4P and colchicine.  
 
Entry Compound Ar1 Ar2 GI50[a] 
1 1 3,4,5-MeOC6H2 4-MeOC6H4 >20 PM 
2 2 3,4,5-MeOC6H2 2-MeOC6H4 >20 PM 
3 3 3,4,5-MeOC6H2 Ph >20 PM 
4 4 3,4,5-MeOC6H2 4-MeC6H4 >20 PM 
5 5 3,4,5-MeOC6H2 3-NO2C6H4 >20 PM 
6 6 3,4,5-MeOC6H2 2-Thiophenyl >20 PM 
7 7 3,4,5-MeOC6H2 4-EtOC6H4 
4.1±0.2 
PM 
8 8 3,4,5-MeOC6H2 2-ClC6H4 >20 PM 
9 9 3,4,5-MeOC6H2 3-H2N-4-MeOC6H3 
315±9   
nM 
10 10 3,4,5-MeOC6H2 3-HO-4-MeOC6H3 
526±14 
nM 
11 11 3-HO-4-MeOC6H3 3,4,5-MeOC6H2 
36±2 nM 
12 12 4-EtOC6H4 3,4,5-MeOC6H2 
1.5±0.05 
PM 
13 13 4-MeOC6H4 3,4,5-MeOC6H2 
336±12  
nM 
14 14 4-MeOC6H4 4-MeOC6H4 >20 PM 
15 15 4-MeOC6H4 
Ph 2.3±0.1  
PM 
16 16 4-MeOC6H4 
2-Thiophenyl >20 PM 
17 17 4-MeOC6H4 
2-ClC6H4 5.2±0.3  PM 
18 18 4-MeOC6H4 
3-NO2C6H4 13.3±0.8 PM 
19 19 4-EtOC6H4 
4-MeC6H4 >20 PM 
20 20 Ph 4-MeC6H4 >20 PM 
21 CA4P -- -- 
8±0.5    
nM 
22 Colchicine -- -- 
25±2    
nM 
23 23 3-[(NaO)2OPO]-4-
MeOC6H3 
3,4,5-MeOC6H2 
51±3 nM 
[a]. HUVECs were plated in 96-multiwell plates and 24 h later they were 
treated with drug or vehicle. At 72 h after treatment, cells were fixed and 
stained with 1% crystal violet, washed and the dye was solubilised in 10% 
acetic acid. Viable cells were quantified by the absorbance at 590 nm. Results 
are a mean of 3 independent experiments ± SEM. 
 
 
Figure 3. Most active sydnone analogs from initial screening. 
Immunofluorescence Studies 
Although proliferation studies on endothelial cells are a useful 
indicator of potential VDA activity, they do not provide 
information on the mechanism of inhibition, in particular with 
respect to tubulin binding. Indeed, the vascular damaging effects 
of VDAs are unlikely to be due to their anti-proliferative activity. 
Instead, effects on cell shape and morphology, and junction 
integrity instigated on a much shorter timescale (within minutes) 
are the most likely cause of VDA-mediated vascular 
collapse.[35,37] A number of previous studies have used tubulin 
depolymerisation assays to support a tubulin binding mode of 
action.[32,38] Although useful in providing evidence of tubulin 
binding, the assays are expensive and require high 
concentrations of drug for an effect to be observed. An 
alternative approach to supplement proliferation studies is to 
visualize the cell cytoskeleton by immunofluorescence. This 
allows drug-induced changes in shape and morphology to be 
observed and effects on specific cellular structures to be 
monitored. The vascular disruptive effects of CA4 are thought to 
arise from microtubule disruption, accompanied by changes in 
cell shape and morphology brought about by remodelling of the 
actin cytoskeleton.[35] Therefore, endothelial cells in culture were 
stained using using phalloidin which stains actin filaments while 
microtubules were stained using an antibody to E-tubulin 
following exposure to the most promising compound identified in 
initial screens (11) alongside CA4P and colchicine.  
In vehicle treated controls, microtubules originate from the 
centrosome and radiate to the edge of the cell (Figure 4, A), 
whereas actin filaments are mostly pericellular (Figure 4, B). 
Upon treatment with 0.5 PM CA4P for 30 minutes, microtubules 
became disrupted (Figure 4, C), resulting in changes to cellular 
morphology as we have shown before.[35,37] Disruption of 
microtubules resulted in the formation of actin stress fibres 
across the cells (Figure 4, D). Colchicine was slower acting than 
CA4P, with a 30 minute treatment resulting in contraction of the 
cells (Figure 4, E and F). Many microtubules remained intact at 
this time point. A longer treatment of 90 minutes afforded results 
that resembled a 30 minute treatment with CA4P (Figure 4, G 
and H). At concentrations of 0.5 PM, 11 instigated similar levels 
of microtubule disruption and morphological changes to CA4P 
(Figure 4, I). There was also clear formation of actin stress fibres 
(Figure 4, J). With evidence that 11 could instigate tubulin 
depolymerisation, we sought to further probe the action of this 
compound. 
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Figure 4. Drug effects on HUVEC cytoskeletal structures. Cells were treated 
with a single dose of either vehicle (A, B), 500 nM CA4P (C, D), 1 PM 
colchicine (E, F, G, H), 0.5 PM drug 11 (I, J). Drug treatments were for 30 min 
with CA4P (C, D), colchicine (E, F) and drug 11 (I, J) and 90 minutes with 
colchicine (G, H). Cells were fixed and stained with an antibody to E-tubulin (A, 
C, E, G, I) and F-actin (B, D, F, H, J). 
Recovery Experiments 
The lower toxicity of CA4P relative to colchicine is thought to be 
due to the differences in the reversibility of binding to tubulin.39 
Colchicine is thought to bind strongly and irreversibly, whereas 
CA4P appears to bind reversibly. Therefore, we tested the 
reversibility of the binding of 11 to tubulin using 
immunofluorescence in parallel with both CA4P and colchicine.  
As shown above, thirty minutes treatment with 0.5 PM CA4P or 
11 resulted in marked changes in cellular morphology (Figure 4). 
Significant recovery of microtubules and a reduction in actin 
stress fibres was observed when the cells were allowed sixty 
minutes to recover after removal of CA4P (Figure 5, A and B). In 
contrast, cells treated for thirty minutes with colchicine, followed 
by removal of the drug and sixty minutes incubation drug-free 
did not show any signs of recovery (Figure 5, C and D). With 
CA4P and colchicine exhibiting a marked difference in recovery 
profile, we next sought to identify if 11 was a reversible tubulin 
binder. Pleasingly, allowing the cells sixty minutes recuperation 
after a thirty minute treatment with 11 led to significant recovery 
of cellular structure and microtubules (Figure 5, E and F). This 
was indicative of reversible binding, similar to that of CA4P, and 
provided evidence of a similar mechanism of action. It also 
provided some indication that 11 would not suffer from the same 
toxicity profile as colchicine. 
 
Figure 5. Recovery of cytoskeletal structures after drug removal. Cells were 
treated with a single dose of either 1 PM CA4P (A, B), 1 PM colchicine (C, D) 
or 1 PM drug 11 (E, F). Drug treatments were for 30 min. Cells were then 
washed with serum containing medium (3 x) and allowed to recover for 60 min. 
Cells were fixed and stained with an antibody to E-tubulin (A, C, E) and F-actin 
(B, D, F). 
Endothelial Monolayer Permeability Experiments 
The activity of VDAs stems from their ability to disrupt the 
endothelial cell monolayer of tumor blood vessels.[35] Therefore, 
in order to quantify this effect, studies in relation to cell 
monolayer permeability to fluorescent dextran were undertaken. 
Confluent HUVEC monolayers were treated for 30 minutes 
before removal of the drug and addition of the fluorescent dye 
for a further 30 minutes. The results showed that the addition of 
a 1 PM solution of both 11 and CA4P significantly increased the 
amount of fluorescent dye passing through the cell monolayer 
(Figure 6), indicating a clear increase in permeability. 
 
Figure 6. Drug-induced changes in endothelial monolayer permeability 
comparing CA4P and 11. Confluent monolayers of cells grown on microporous 
filter inserts were treated with vehicle control, CA4P (1 PM, 30 min) or 
compound 11 (1 PM, 30 min).  Drugs were removed and replaced with FITC ±
dextran for a further 30 min. The passage of FITC-dextran through the 
monolayer was quantified and expressed as a percentage of FITC that passed 
through a filter without cells. Results are a mean of 3 independent experiments 
± SEM. *represents P < 0.05 for the significance of differences between 
groups (one-way ANOVA followed by a Tukey post-test). 
Analysis of Rho-GTPase/Rho Kinase Signaling Pathway 
Activation 
Next, we decided to examine whether 11 acted by triggering 
similar signalling pathways to those observed in CA4P. We have 
previously shown that activation of the RhoA-GTPase signal 
pathway was involved in actin remodelling caused by CA4P.[35] 
Actin polymerization and the phosphorylation of myosin light 
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chain (MLC) resulted in stress fiber formation. The activity was 
modulated by serine/threonine Rho kinases (ROCKs) The 
activation of the RhoA-ROCK pathway by CA4P was confirmed 
by increases in MLC phosphorylation upon exposure to the 
drug.[35] Therefore, we decided to investigate drug induced 
increases in the phosphorylation of MLC in HUVECs for both 11 
and CA4P. It was found that both compounds instigated 
significant increases in the phosphorylation of MLC at various 
concentrations, indicating that both compounds were activating 
the same pathway (Figure 7). CA4P significantly increased 
levels of pMLC starting at 0.25 PM, however no effect was 
observed at 0.025 PM. Drug 11 was found to be slightly less 
active, failing to instigate increases in levels of pMLC at 0.25 PM. 
However, at 0.5 PM 11 instigated significant increases in pMLC. 
 
Figure 7. Drug-induced induction of phosphorylation of Rho kinase target MLC. 
HUVECs were treated with increasing concentrations of drug 11 or CA4P for 
15 min after which proteins were extracted and analyzed for phosphorylation 
of ROCK target MLC (pMLC) by Western blotting using an antibody specific to 
the phosphorylated form of the protein (A). Immunoblots were reprobed with 
an antibody to actin to confirm equal loading. pMLC band intensities were 
analyzed by ImageJ and results expressed as fold-change over control cells 
WUHDWHG ZLWK YHKLFOH DORQH % (DFK FROXPQ UHSUHVHQWV WKH PHDQ RI í
independent cell culture experiments ± SEM. כrepresents P < 0.05 for the 
significance of differences between drug treatment groups and controls (paired 
Tukey post-test). 
In order to further confirm that the phosphorylation of MLC was 
induced by activation of ROCK upon treatment with 11, cells 
were treated with a specific ROCK inhibitor, Y-27632, before 
incubation with 11. As was observed previously with CA4P,[35] 
drug 11- and CA4P-induced phosphorylation of MLC was 
abrogated in the presence of Y-27632. Thus, confirming that 
ROCK is involved in the process. 
 
Figure 8. HUVECs were incubated with Rho kinase inhibitor Y-ȝ0
for 5 min and then treated with 1 PM CA4P or 11 for 15 min. Proteins were 
extracted and analyzed for pMLC by Western blotting using an antibody 
specific to the phosphorylated form of the protein. 
In Vivo Studies 
To validate the results observed in vitro, experiments were 
undertaken to determine the activity of the drug in vivo. Due to 
the limited solubility of 11 in PBS, it was derivatized to the 
disodium phosphate compound 23 for in vivo studies. The 
maximum tolerated dose (MTD) of 23 in SCID (severe combined 
immunodeficiency) mice was found to be greater than 339 
mg/kg (0.681 mmol/kg; data not shown). We next investigated 
whether 23 showed efficacy in a tumor model. SCID mice were 
implanted with 5 x 106 SW1222 (human colorectal 
adenocarcinoma) cells via subcutaneous injection. Tumors were 
allowed to reach 8 mm in diameter and then treated with either 
vehicle (50% Na2CO3/NaCl), CA4P (100 mg/kg, 0.227 mmol/kg) 
or a solution of 23 (339 mg/kg, 0.681 mmol/kg). Tumors were 
excised 24 hours later and necrosis levels calculated in H&E 
stained 5 µm thick sections by a random point scoring 
PLFURVFRS\ PHWKRG XVLQJ D µ&KDONOH\¶ H\HSLHFH JUDWLFXOH[40,41] 
As shown in Figure 9, CA4P treated tumors were significantly 
more necrotic than the untreated tumors, However, treatment 
with 23 did not have an effect on tumor necrosis. Such a lack of 
response to 23 indicated that the compound may not have 
reached the tumor blood vessels and was either metabolized 
before it could act or it was rapidly excreted. Only limited 
examples of mesoionic compounds have been tested in vivo[42,43] 
and their unusual structure makes it difficult to predict their 
pharmacokinetic profile and stability in the body. Nonetheless, 
this class of heterocycle has been a popular target in medicinal 
chemistry over several years, and the establishment of a viable 
administration route is therefore an important issue to address in 
the field. Further advances in this area are the subject of active 
investigation.[47, 48] 
 
Figure 9. In Vivo Study of Drug-Induced effects on Tumor Cell Necrosis 
Comparing CA4P and 23. Each point represents the combined data from a 
single tumor. 5 sections (cut at different tumor depths) were analyzed per 
tumor using a x20 objective on a Nikon Eclipse TS100 microscope. The total 
section was analyzed and % necrosis calculated in each field from the relative 
number of points in a Chalkley eyepiece graticule co-incident with necrotic 
versus viable tumor tissue. Bars represent the mean±SEM of the combined 
data for each tumor. *represents P < 0.05 for the significance of differences 
between groups (one-way ANOVA followed by a Tukey post-test). 
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Conclusions 
We have successfully prepared a range of diarylsydnones and 
tested their potential as tubulin binders in vitro. The most potent 
compound in the initial screen, 11, showed promising activity 
and was shown to disrupt microtubules and affect cellular 
morphology at sub-micromolar levels. Its binding to tubulin was 
shown to be reversible, in a similar manner to combretastatin A4. 
Like CA4P, 11 also significantly increased endothelial cell 
monolayer permeability. The compound was derivatized to the 
corresponding phosphate salt 23, but did not exhibit efficacy in 
vivo, possibly due to rapid metabolism. Further investigations 
are required on the stability of sydnones in animals to establish if 
the motif is viable for future therapeutics. 
Experimental Section 
General. 1H NMR spectra were recorded on a Bruker AVIII HD 400 (400 
MHz), Bruker AVI 400 (400 MHz), or DPX-400 (400 MHz) supported by 
an Aspect 3000 data system. Chemical shifts are reported in parts per 
million (ppm) from tetramethylsilane with the residual protic solvent 
resonance as the internal standard (CHCl3į'062į 13C 
NMR spectra were recorded on a Bruker AVIII HD 400 (100.6 MHz), 
Bruker AVI 400 (100.6 MHz), or DPX-400 (100.6 MHz) with complete 
proton decoupling. Chemical shifts are reported in ppm from 
tetramethylsilane with the solvent as the internal reference (CDCl3 į
77.16; DMSO-d6 į  +LJK-resolution mass spectra (HRMS), 
recorded for accurate mass analysis, were obtained in electrospray mode 
(TOF ES+). Infrared (IR) spectra were recorded on a PerkinElmer 
3DUDJRQ  )7,5 VSHFWURSKRWRPHWHU Ȟmax in cm Ѹ 1. Samples were 
recorded as solids using a solid probe. Bands were characterized as 
broad (br), strong (s), medium (m), and weak (w). Flash chromatography 
was performed on silica gel (BDH silica gel 60 43-60). Thin layer 
chromatography (TLC) was performed on aluminum backed plates 
precoated with silica (0.2 mm, Merck DCalufolien Kieselgel 60 F254) 
which were developed using ultraviolet (UV). All compounds submitted 
for biological testing were recrystallized to consistent melting point and 
judged as >95% pure by 1H and 13C NMR spectroscopy unless otherwise 
specified. Sydnones were prepared by standard methods 
(cyclodehydration of N-nitroso amino acid with trifluoroacetic 
anhydride).[36]  
General Procedure for the Direct Arylation of Sydnones. A mixture of 
sydnone (1 eq.), aryl halide (1.5 eq.), palladium acetate (5 mol %), 
XPhos (10 mol %) and potassium carbonate (2-3 eq.) in DMF (0.1 ± 0.5 
M) under an atmosphere of nitrogen was heated at 80 - 
hours before the reaction was allowed to cool to ambient temperature 
and water was added. The resulting mixture was extracted with ethyl 
acetate:40-60 petroleum ether (9:1) and the combined organic layers 
dried over MgSO4 and concentrated in vacuo. Flash silica 
chromatography (eluting solvent 20%-100% ethyl acetate in 40-60 
petroleum ether) afforded the target 3,4-disubstituted sydnones. The 
compounds could be further purified by recrystallization from ethanol or 
dichloromethane/petrol. 
4-(4-Methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)sydnone (1). N-
(3,4,5-Trimethoxyphenyl)sydnone (114 mg, 0.452 mmol) and 4-
chloroanisole (97 mg, 0.68 mmol) were subjected to the general 
conditions affording 1 as colourless crystals (119 mg, 73%). M.p.: 165-
167 °C (dec.); 1H NMR (400 MHz, CDCl3į +V (3H, s), 
3.92 (3H, s), 6.67 (2H, s), 6.82 ± 6.88 (2H, m), 7.27 ± 7.31 (2H, m);  13C 
NMR (101 MHz, CDCl3į
128.9, 129.9, 140.6, 154.1, 159.9, )7,5Ȟmax 2945 (w), 1723 (m), 
1604 (s), 1232 (s), 1121 (s), 1019 (s), 987 (s); HRMS calculated for 
C18H19N2O6 (ES+)(+H+): 359.1243. Found: 359.1226. 
4-(2-Methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)sydnone (2). N-
(3,4,5-Trimethoxyphenyl)sydnone (200 mg, 0.792 mmol) and 2-
bromoanisole (223 mg, 1.19 mmol) were subjected to the general 
conditions affording 2 as a colourless solid (202 mg, 71%). M.p.: 180-
181 °C (dec.); 1H NMR (400 MHz, CDCl3į +V+V
3.84 (3H, s), 6.60 (2H, s), 6.78 (1H, dd, J = 8.5, 1.5 Hz), 7.03 (1H, td, J = 
7.5, 1.0 Hz), 7.36 (1H, ddd, J = 8.5, 7.5, 1.5 Hz), 7.44 (1H, dd, J = 7.5, 
1.5 Hz). 13C NMR (101 MHz, CDCl3 į    
111.3, 114.0, 121.4, 131.3, 131.4, 131.7, 140.2, 153.6, 156.9, 167.8; 
)7,5 Ȟmax 2941 (b), 2837 (s), 1731 (s), 1607 (m), 1238 (s), 1120 (s), 
HRMS calculated for C18H19N2O6 (ES+)(+H+): 359.1243. Found: 359.1226. 
4-Phenyl-N-(3,4,5-trimethoxyphenyl)sydnone (3). N-(3,4,5-
Trimethoxyphenyl)sydnone (99 mg, 0.39 mmol) and chlorobenzene (66 
mg, 0.59 mmol) were subjected to the general conditions affording 3 as a 
tan solid (124 mg, 81%). M.p.: 146-147 °C (dec.); 1H NMR (400 MHz, 
CDCl3į+V+V+V-7.39 (5H, m); 13C 
NMR (101 MHz, CDCl3į
 )7,5Ȟmax 2945 (w), 1746 (s), 1603 
(s), 1232 (s), 1125 (s), 977 (s); HRMS calculated for C17H17N2O5 
(ES+)(+H+): 329.1137. Found: 329.1125. 
4-(4-Tolyl)-N-(3,4,5-trimethoxyphenyl)sydnone (4).30 N-(3,4,5-
Trimethoxyphenyl)sydnone (151 mg, 0.599 mmol) and 4-chlorotoluene 
(114 mg, 0.901 mmol) were subjected to the general conditions affording 
4 as colourless crystals (196 mg, 96%). M.p.: 140-141 °C (dec.) (Lit.[30] 
140±141 °C); 1H NMR (400 MHz, CDCl3 į  + V  + V
3.91 (3H, s), 6.67 (2H, s), 7.10 (2H, d, J = 8.0 Hz), 7.22 (2H, d, J = 8.0 
Hz); 13C NMR (101 MHz, CDCl3į
127.3, 129.5, 130.0, 139.0, 140.7, 154.1, 167.1; FTIR Ȟmax  2942 (w), 
2840 (w), 1749 (s), 1128 (s), 984 (m); HRMS calculated for C18H18N2O5 
(TOF ES+)(+H+): 343.1294. Found: 343.1283. 
4-(3-Nitrophenyl)-N-(3,4,5-trimethoxyphenyl)sydnone (5). N-(3,4,5-
Trimethoxyphenyl)sydnone (103 mg, 0.408 mmol) and 1-chloro-3-
nitrobenzene (96 mg, 0.61 mmol) were subjected to the general 
conditions affording 5 as orange crystals (137 mg, 90%). M.p.: 148-
149 °C; 1H NMR (400 MHz, CDCl3į+V+V+
s), 7.52 (1H, td, J = 8.0, 1.0 Hz), 7.76-7.82 (1H, m), 8.08-8.15 (2H, m); 
13C NMR (101 MHz, CDCl3 į      
)7,5Ȟmax 1748 
(s), 1731 (s), 1605 (m), 1535 (s), 1352 (s), 1265 (s), 1230 (s), 1126 (s), 
987 (m); HRMS calculated for C17H16N3O7 (ES+)(+H+): 374.0988. Found: 
374.0990. 
4-(Thiophen-2-yl)-N-(3,4,5-trimethoxyphenyl)sydnone (6). N-(3,4,5-
Trimethoxyphenyl)sydnone (103 mg, 0.410 mmol) and 2-chlorothiophene 
(73 mg, 0.62 mmol) were subjected to the general conditions affording 6 
as yellow crystals (111 mg, 81%). M.p.: 173-174 °C; 1H NMR (400 MHz, 
CDCl3į+V+V+V+GWJ = 5.0, 4.0 
Hz), 7.26 (1H, dd, J = 5.0, 1.0 Hz), 7.39 (1H, dd, J = 4.0, 1.0 Hz);  13C 
NMR (101 MHz, CDCl3į
   )7,5Ȟmax 3094 (w), 2943 (w), 2835 
(w), 1746 (s), 1605 (m), 1235 (s), 1127 (s), 998 (w); HRMS calculated for 
C15H15N2O5S (ES+)(+H+): 335.0702. Found: 335.0704. 
4-(4-Ethoxyphenyl)-N-(3,4,5-trimethoxyphenyl)sydnone (7). N-(3,4,5-
Trimethoxyphenyl)sydnone (200 mg, 0.792 mmol) and 4-bromophenetole 
(239 mg, 1.19 mmol) were subjected to the general conditions affording 7 
as a tan solid (272 mg, 92%). M.p.: 143-144 °C (dec.); 1H NMR (400 
MHz, CDCl3į+ WJ = 7.0 Hz), 3.78 (6H, s), 3.92 (3H, s), 4.01 
(2H, q, J = 7.0 Hz), 6.67 (2H, s), 6.80-6.86 (2H, m), 7.24-7.30 (2H, m); 
13C NMR (101 MHz, CDCl3į
       )7,5 Ȟmax 2985 (w), 
2941 (w), 1749 (s), 1600 (m), 1231 (s), 1125 (s), 999 (m), 978 cm-1 (s); 
HRMS calculated for C18H19N2O6 (ES+)(+H+): 373.1400. Found: 373.1408. 
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4-(2-Chlorophenyl)-N-(3,4,5-trimethoxyphenyl)sydnone (8). N-(3,4,5-
Trimethoxyphenyl)sydnone (101 mg, 0.399 mmol) and 1,2-
dichlorobenzene (88 mg, 0.60 mmol) were subjected to the general 
conditions affording 8 as a colourless solid (105 mg, 73%). M.p.: 135-
136 °C; 1H NMR (400 MHz, CDCl3į+V+V+
s), 7.29-7.45 (4H, m);  13C NMR (101 MHz, CDCl3į  
105.7, 124.3, 127.6, 129.9, 130.3, 131.7, 132.9, 135.7, 140.6, 153.7, 
)7,5Ȟmax 3058 (w), 2943 (w), 1757 (s), 1608 (m), 1234 (m), 1130 
(s), 1049 (w), 988 (m); HRMS calculated for C17H16[35]ClN2O5 (ES+)(+H+): 
363.0748. Found: 363.0736. 
4-(3-Amino-4-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)sydnone 
(9). N-(3,4,5-Trimethoxyphenyl)sydnone (100 mg, 0.396 mmol) and 5-
bromo-2-methoxyaniline (120 mg, 0.595 mmol) were subjected to the 
general conditions affording 9 as an orange solid (135 mg, 91%). M.p.: 
173-174 °C; 1H NMR (400 MHz, CDCl3į+V+V
(2H, s), 3.90 (3H, s), 6.52 (1H, dd, J = 8.5, 2.0 Hz), 6.64 (1H, d, J = 8.5 
Hz), 6.68 (2H, s), 6.85 (1H, d, J = 2.0 Hz); 13C NMR (101 MHz, CDCl3į
55.6, 56.6, 61.2, 102.5, 108.4, 110.2, 113.4, 117.1, 118.1, 130.1, 136.6, 
    )7,5 Ȟmax 3471 (w), 3367 (w), 2941 (w), 
2838 (w), 1732 (s), 1606 (m), 1224 (s), 1127 (s); HRMS calculated for 
C18H20N3O6 (ES+)(+H+): 374.1352. Found: 374.1353. 
4-(3-Hydroxy-4-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)sydnone 
(10). N-(3,4,5-Trimethoxyphenyl)sydnone (500 mg, 1.98 mmol) and 5-
bromo-2-methoxyphenol (604 mg, 2.97 mmol) were subjected to the 
general conditions. Flash silica chromatography (eluting solvent 10%-
30% ethyl acetate in dichloromethane) afforded 10 as a yellow solid (599 
mg, 81%). M.p.: 237-239 °C (dec.); 1H NMR (400 MHz, DMSO): į
(9H, s), 3.76 (3H, s), 6.71 (1H, dd, J = 8.5, 2.0 Hz), 6.88 (1H, d, J = 2.0 
Hz), 6.91 (1H, d, J = 8.5 Hz), 7.13 (2H, s), 9.28 (1H,s);  13C NMR (101 
0+] '062 į        
118.5, 129.9, 139.8, 146.3, 148.1,   )7,5 Ȟmax 3415 (br), 
3062 (w), 2947 (w), 1718 (s), 1605 (m), 1243 (s), 1125 (s), 1014 (s), 949 
(m);  HRMS calculated for C18H19N2O7 (ES+)(+H+): 375.1192. Found: 
375.1192.  
 4-(3,4,5-Trimethoxyphenyl)-N-(3-hydroxy-4-
methoxyphenyl)sydnone (11).[36] N-(3-Hydroxy-4-
methoxyphenyl)sydnone (473 mg, 2.27 mmol) and 5-bromo-1,2,3-
trimethoxybenzene (842 mg, 3.41 mmol) were subjected to the general 
conditions affording 11 as a colourless solid (402 mg, 47%). M.p.: 196-
197 °C (Lit.[36] 196±197 °C);  1H NMR (400 MHz, CDCl3į+V
3.83 (3H, s), 4.00  (3H, s), 5.94 (1H, s), 6.59 (2H, s), 6.92-7.05 (2H, m), 
7.09 (1H, s); 13C NMR (101 MHz, CDCl3į
111.0, 111.7, 117.2, 119.9, 127.8, 138.5, 147.0, 149.5, 153.3, 167.2; 
)7,5Ȟmax 3295 (br), 3082 (w), 2940 (w), 2836 (w), 1710 (s), 1600 (w), 
1581 (m), 1509 (s), 1229 (s), 1125 (s) 1014 (m), 998 (m); HRMS 
calculated for C18H19N2O7 (ES+)(+H+): 375.1192. Found: 375.1181. 
4-(3,4,5-Trimethoxyphenyl)-N-(4-ethoxyphenyl)sydnone (12). N-(4-
Ethoxyphenyl)sydnone (102 mg, 0.494 mmol) and 5-bromo-1,2,3-
trimethoxybenzene (149 mg, 0.741 mmol) were subjected to the general 
conditions affording 12 as colourless crystals (140 mg, 76%). M.p.: 129-
130 °C (dec.); 1H NMR (400 MHz, CDCl3į5 (3H, t, J = 7.0 Hz), 3.63 
(6H, s), 3.80 (3H, s), 4.09 (2H, q, J = 7.0 Hz), 6.54 (2H, s), 6.98-7.08 (2H, 
m), 7.37-7.45 (2H, m); 13C NMR (101 MHz, CDCl3 į  
64.4, 104.6, 107.8, 115.7, 120.0, 126.2, 127.1, 138.4, 153.3, 161.6, 
166.8; FTIR: Ȟmax 2984 (w), 2937 (w), 2834 (w), 1743 (s), 1583 (m), 1250 
(m), 1126 (s), 1046 (w), 1002 (w); HRMS calculated for C19H21N2O6 
(ES+)(+H+): 373.1400. Found: 373.1411. 
4-(3,4,5-Trimethoxyphenyl)-N-(4-methoxyphenyl)sydnone (13). N-(4-
Methoxyphenyl)sydnone (100 mg, 0.521 mmol) and 5-bromo-1,2,3-
trimethoxybenzene (193 mg, 0.781 mmol) were subjected to the general 
conditions affording 13 as an yellow solid (132 mg, 71%). M.p.: 155-
157 °C (dec.); 1H NMR (400 MHz, CDCl3į +V+V
3.89 (3H, s), 6.55 (2H, s), 7.03-7.10 (2H, m), 7.41-7.47 (2H, m). 13C NMR 
(101 MHz, CDCl3į
   )7,5Ȟmax 3116 (w), 3091 (w), 2944 
(w), 2841 (w), 1729 (s), 1578 (s), 1125 (s), 991 (m); HRMS calculated for 
C18H19N2O6 (ES+)(+H+): 359.1243. Found: 359.1239. 
3,4-Bis(4-methoxyphenyl)sydnone (14).[30] N-(4-
Methoxyphenyl)sydnone (1.00 g, 5.21 mmol) and 4-chloroanisole (0.99 g, 
7.8 mmol) were subjected to the general conditions affording 14 as a tan 
solid (1.51 g, 97%). M.p.: 136-137 °C (dec.) (Lit.[30] 136±137 °C); 1H NMR 
(400 MHz, CDCl3į+V+V± 6.86 (2H, m), 6.98 
± 7.06 (2H, m), 7.20± 7.26 (2H, m), 7.35 ± 7.43 (2H, m); 13C NMR (101 
MHz, CDCl3 į   108.0, 114.4, 115.2, 117.0, 126.3, 127.4, 
129.0, 159.8, 162.1, 167.4. 
4-Phenyl-N-(4-methoxyphenyl)sydnone (15).[30] N-(4-
Methoxyphenyl)sydnone (105 mg, 0.547 mmol) and chlorobenzene (92 
mg, 0.82 mmol) were subjected to the general conditions affording 14 as 
a pink solid (122 mg, 83%). M.p.: 106-107 °C (dec) (Lit.[30] 106-
1H NMR (400 MHz, CDCl3į+V+GJ = 9.0 Hz), 7.30 
(5H, s), 7.39 (2H, d, J = 9.0 Hz); 13C NMR (101 MHz, CDCl3 į 
107.8, 115.3, 124.8, 126.3, 127.4, 127.5, 128.7, 128.9, 162.2, 167.3. 
4-(Thiophen-2-yl)-N-(4-methoxyphenyl)sydnone (16).[30] N-(4-
Methoxyphenyl)sydnone (101 mg, 0.526 mmol) and 2-chlorothiophene 
(93 mg, 0.78 mmol) were subjected to the general conditions affording 16 
as orange crystals (128 mg, 89%). M.p.: 129 °C (Lit.[30] 1H NMR 
(400 MHz, CDCl3į+V+GWJ = 5.0, 4.0 Hz), 7.11 (2H, 
d, J = 9.0 Hz), 7.23 (1H, dd, J = 5.0, 1.0 Hz), 7.33 (1H, dd, J = 4.0, 1.0 
Hz), 7.46 (2H, d, J = 9.0 Hz);  13C NMR (101 MHz, CDCl3į0, 106.6, 
)7,5Ȟmax 
3080 (w), 2941 (w), 2840 (w), 1756 (s), 1735 (s), 1176 (m), 1017 (s), 991 
(m); HRMS calculated for C13H10N2O3S (TOF ES+)(+H+): 275.0490. 
Found: 275.0503. 
4-(2-Chlorophenyl)-N-(4-methoxyphenyl)sydnone (17).[30] N-(4-
Methoxyphenyl)sydnone (102 mg, 0.531 mmol) and 1,2-dichlorobenzene 
(117 mg, 0.796 mmol) were subjected to the general conditions affording 
17 as an orange oil (151 mg, 94%). 1H NMR (400 MHz, CDCl3į
(3H, s), 6.91 (2H, d, J = 9.0 Hz), 7.27-7.40 (6H, m); 13C NMR (101 MHz, 
CDCl3 į         
    )7,5 Ȟmax 3066 (w), 2936 (w), 2843 (w), 
1757 (s), 1743 (s), 1028 (m), 1002 (m); HRMS calculated for 
C15H12N2O335Cl (TOF ES+)(+H+): 303.0536. Found: 303.0524. 
4-(3-Nitrophenyl)-N-(4-methoxyphenyl)sydnone (18).[30] N-(4-
Methoxyphenyl)sydnone (104 mg, 0.542 mmol) and 1-chloro-3-
nitrobenzene (128 mg, 0.812 mmol) were subjected to the general 
conditions affording 18 as a yellow solid (144 mg, 85%). M.p.: 152-
153 °C (dec.) (Lit.[30] 152- 1H NMR (400 MHz, CDCl3į+
s), 7.09 (2H, d, J = 9.0 Hz), 7.43 (2H, d, J = 9.0 Hz), 7.50 (1H, t, J = 8.0 
Hz), 7.75 (1H, d, J = 8.0 Hz), 8.02-8.12 (2H, m);  13C NMR (101 MHz, d6-
'062 į         
132.8, 147.6, 161.9, 166.2. 
4-(4-Tolyl)-N-(4-ethoxyphenyl)sydnone (19).[30] N-(4-
Ethoxyphenyl)sydnone (127 mg, 0.616 mmol) and 4-chlorotoluene (117 
mg, 0.924 mmol) were subjected to the general conditions affording 19 
as a tan solid (140 mg, 77%). M.p.: 123-124 °C (dec.) (Lit.[30] 123-124 
1H NMR (400 MHz, CDCl3į+WJ = 7.0 Hz), 2.29 (3H, s,), 
4.09 (2H, q, J = 7.0 Hz), 6.94-7.02 (2H, m), 7.08 (2H, d, J = 8.0 Hz), 7.18 
(2H, d, J = 8.0 Hz), 7.30-7.39 (2H, m); 13C NMR (101 MHz, CDCl3į
21.4, 64.3, 108.0, 115.6, 121.9, 126.2, 127.2, 127.3 129.5, 138.8, 161.5, 
)7,5Ȟmax 2981 (w), 2934 (w), 1737 (s), 1115 (m), 1041 (m), 1002 
(m); HRMS calculated for C17H16N2O3 (TOF ES+)(+H+): 297.1239. Found: 
297.1249. 
4-(4-Tolyl)-N-phenylsydnone (20).[30] N-Phenylsydnone (102 mg, 0.629 
mmol) and 4-chlorotoluene (119 mg, 0.940 mmol) were subjected to the 
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general conditions affording 20 as a tan solid (131 mg, 83%). M.p.: 134-
136 °C (dec.) (Lit.[30] 141- 1H NMR (400 MHz, CDCl3į+
s), 7.08 (2H, d, J = 8.0 Hz), 7.16 (2H, d, J = 8.0 Hz), 7.47 (2H, d, J = 7.5 
Hz), 7.57 (2H, t, J = 7.5 Hz), 7.60-7.70 (1H, m); 13C NMR (101 MHz, 
CDCl3 į  108.2, 121.6, 125.0, 127.4, 129.5, 130.2, 132.1, 134.8, 
139.0, 167.3. 
4-(3,4,5-Trimethoxyphenyl)-N-(3-O-phosphate[sodium salt]-4-
methoxyphenyl)sydnone (23). To a suspension of 11 (73 mg, 0.20 
mmol) in CH2Cl2 (1 mL) was added a solution of phosphorous oxychloride 
(179 mg, 1.17 mmol) in CH2Cl2 (1 mL) dropwise and the reaction stirred 
for one hour at room temperature. Triethylamine (47 mg, 0.47 mmol) was 
added and the reaction stirred at room temperature for 16 hours. Water 
was added and the reaction mixture extracted with CH2Cl2. Volatiles were 
removed in vacuo, and the crude material dissolved in a minimum of 
acetonitrile. Amberlite IR-120 Na+ form (200 mg) in water was added and 
the reaction stirred at room temperature for 16 hours. The mixture was 
filtered and volatiles removed in vacuo. The resulting solid was 
recrystallized from acetone affording 23 as a yellow solid (78 mg, 80%). 
N.B. the compound was contaminated with a small amount of 
inseparable trisodium phosphate. 1H NMR (400 MHz, D22į+V, 
3.78 (3H, s), 3.94 (3H, s),  6.63 (2H, s), 7.24 (1H, d, J = 9.0 Hz), 7.32 (1H, 
app d, J = 9.0 Hz), 7.52 (1H, app s); 13C NMR (101 MHz, D22į
56.3, 60.9, 105.6, 109.5, 113.2, 118.0, 119.6, 121.7, 125.8, 137.4, 141.8 
(d, J = 7.0 Hz), 152.6, 153.7 (d, J = 5.0 Hz), 168.8; 31P NMR (162 MHz, 
D22į-)7,5Ȟmax 3397 (br), 2949 (w), 1732 (s), 1580 (m), 1509 (s), 
1283 (m), 1122 (s), 1109 (s), 946 (s); HRMS calculated for 
C18H17N2Na2O10P (TOF ES+)(+H+): 499.0494. Found: 499.0473.  
2-Methoxy-5-((3,4,5-trimethoxyphenyl)ethynyl)phenol (22). A solution 
of 21 (8.05 g, 30.7 mmol), 1-bromo-3,4,5-trimethoxybenzene (5.05 g, 
20.5 mmol), palladium acetate (0.09 g, 0.4 mmol) and triphenylphosphine 
(0.24 g, 0.8 mmol) in pyrollidine (60 mL) was heated at reflux for one 
hour. Aqueous NH4Cl was added and the reaction mixture extracted with 
ethyl acetate. The organic phase was washed with aqueous HCl, dried 
over MgSO4 and volatiles removed in vacuo. Flash silica chromatography 
(eluting solvent 40% ethyl acetate in 40-60 petroleum ether) afforded 22 
as orange crystals (6.10 g, 95%). M.p. 97-99 °C (lit.[44] 1H NMR 
(400 MHz, CDCl3į+V+V+V+V
6.75 (2H, s), 6.82 (1H, d, J = 8.5 Hz), 7.06 (1H, dd, J = 8.5, 2.0 Hz), 7.09 
(1H, d, J = 2.0 Hz); 13C NMR (101 MHz, CDCl3į
88.5, 108.7, 110.6, 116.0, 117.6, 118.6, 124.3, 138.6, 145.4, 147.1, 
153.1.  
Biological Methods and Materials 
Endothelial Cell Culture. Human Umbilical Vein Endothelial Cells 
(HUVECs) from pooled donors were purchased from Promocell GmbH 
(Promocell, C-12203) and cultured as we described before.[36] Briefly, 
cells were maintained for up to a maximum of six passages in endothelial 
cell basal medium (EBM) (Promocell, C-22010) supplemented with 
Endothelial Cell Growth Supplement Mix (Promocell, C-39215) and an 
extra 8% (v/v) low-endotoxin foetal calf serum (Invitrogen).  
Immunofluorescence staining of the endothelial cytoskeleton. 
Changes in cell morphology and the cytoskeleton were visualised by dual 
staining of microtubules and actin filaments as we described 
previously.[35,36] Briefly, HUVECs were plated in Permanox Lab-Tek 
were allowed to reach confluence before they were exposed to drug or 
vehicle for 30 min. Cells were then fixed in 3.7% formalin in PBS and 
stained using an anti- -tubulin antibody (Sigma, T4026) and Texas Red-
X Phalloidin (Invitrogen, T7471). Cells were imaged using an Olympus 
BX microscope using CelOA) VRIWZDUH )RU DQDO\VLV RI µUHFRYHU\¶ RI
cytoskeletal structures, drug treated cells were washed several times 
with fresh medium containing serum and incubated at 37oC for up to 90 
min as we described before.[36] 
Cell Proliferation Studies. The effects of drugs on cell growth inhibition 
were established as we described previously.[36] HUVECs were plated in 
96-multiwell plates (5 x 103 cells/well) and 24 h later they were treated 
with drug or vehicle. At 72 h after treatment cells were fixed and stained 
with 1% crystal violet (Sigma, Cat: C3886) solution in 10% ethanol. After 
several washes in PBS, the dye was solubilised in 10% acetic acid and 
absorbance was read at 590 nm. GI50 values were established for each 
drug using GraphPad Prism software.  
Endothelial Monolayer Permeability Assay. Confluent HUVEC 
monolayers were established in fibronectin-
inserts (Falcon, 353492) set in companion 24-multiwell plates (Falcon, 
353504) as described previously.[35,36] Drugs or vehicle were added 
directly to the cells within the inserts for 30 min before replacing the 
medium with fresh medium containing 0.8 mg/mL FITC-dextran (Sigma: 
46945) and incubating the cells in this for a further 30 min. Fluorescence 
(excitation 488, emission 525) was quantified in samples of media taken 
from the lower well.  
Analysis of pMLC phosphorylation by Western Blotting. Confluent 
HUVECs maintained in 12-multiwell plates were treated with drugs or 
vehicle for 20 min before proteins were extracted and analysed for MLC 
phosphorylation by western blotting using an antibody to dually 
phosphorylated MLC (Cell Signalling, ݡ 3674) as described 
previously.[35,36] Blots were stripped and reprobed using an antibody to 
actin (Sigma, A4700).  
In Vivo Analysis and Necrosis Scoring. Animal experiments were 
conducted in accordance with the UK Animals (Scientific Procedure) Act 
1986, with local ethics committee approval and following published 
guidelines for the use of animals in cancer research.[45] Female severe 
combined immunodeficiency (SCID) mice (8±12 weeks old, 20±25 g) 
were implanted subcutaneously into the rear dorsum with human 
colorectal adenocarcinoma SW1222 cells (5 × 106 cells in 0.05 mL) as 
described.[36,46] Once tumors reached approximately 8 mm in mean 
diameter animals were administered intraperitoneally with a single dose 
of either vehicle (50% Na2CO3/NaCl, 10 mL/kg), CA4P (100 mg/kg, 0.227 
mmol/kg, in 50% Na2CO3/NaCl, 10 mL/kg) or a solution of 23 (339 mg/kg, 
0.681 mmol/kg, 50% Na2CO3/NaCl, 10 mL/kg). Tumors were excised 24 
hours after treatment and were formalin-fixed, paraffin-embedded, and 
hematoxylin and eosin (H & E) stained. The percentage of necrosis was 
quantified according to a random points scoring (Chalkley) system.[40]  
Statistics. Statistical analysis was carried out using GraphPad Prism 6 
for Windows 8.1. The significance of differences between groups was 
assessed using one-way ANOVA followed by a Tukey post-test, with 
p<0.05 considered significant. 
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Cis is the answer! A family of novel configurationally fixed combretastatin analogs has been prepared that is based on a sydnone 
heterocycle core. The most potent analog was found to display tubular binding and disruption, and to affect cellular morphology and 
permeability in a similar manner to combretastatin A4. 
